Ameliorate hepatic inflammation in NAFLD rats by blocking the TLR4/NF-κB/NLRP3 pathway, with multi-components and multi-targets action pattern. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.